This website is intended for journalists outside the US/UK/Canada, who are interested in media information from Boehringer Ingelheim.

Top Stories

 

  •   

    EC approval for Boehringer Ingelheim’s oncology treatment

  •  

    The Power of 140 Characters: When Social Media met the ESC Congress 2014

    Events and Initiatives

    EC approval for Boehringer Ingelheim’s oncology treatment

    27 November 2014
    Find out the latest news about Boehringer Ingelheim’s treatments in oncology

    Education Hub

     

     

    INFOGRAPHIC

    Nintedanib* Lume-Lung
    1 Clinical Trial

    INFOGRAPHIC

    Afatinib* Lux-Lung 3 & 6
    Clinical Trials

    Tweets from @Boehringer